Publications by authors named "Delphine Issard"

Claim this Profile
D
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Gavin Giovannoni, Barry A Singer, Delphine Issard, Dominic Jack, Patrick Vermersch

Mult Scler· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
Giancarlo Comi, Nicola De Stefano, Mark S Freedman, Frederik Barkhof, Bernard M J Uitdehaag, Delphine Issard

J Neurol Neurosurg Psychiatry· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
Ludwig Kappos, Jens Kuhle, Juha Multanen, Marcelo Kremenchutzky, Elisabetta Verdun di Cantogno, Delphine Issard

J Neurol Neurosurg Psychiatry· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
Nicola De Stefano, Maria Pia Sormani, Bettina Stubinski, Gregg Blevins, Jelena S Drulovic, Delphine Issard

J Neurol Sci· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.
Nicola De Stefano, François Curtin, Bettina Stubinski, Gregg Blevins, Jelena Drulovic, Delphine Issard

Mult Scler· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis